Marta Crespo
@MartaCrespoHEM
Followers
1K
Following
8K
Media
203
Statuses
3K
Research Scientist at the Experimental Hematology lab in Vall d’Hebron Institut of Oncology (VHIO)
Barcelona, Spain
Joined June 2014
LAB-PI (Laboratory Prognostic Index): A single blood test including LDH, Hb, and B2M predicts prognosis in newly diagnosed #DLBCL | @ESMO_Open 🗞️ Collaborative study on behalf of @geltamo
https://t.co/pylgNvqjoL
5
14
39
Job alert! 🖥️We look for a motivated bioinformatician postdoc to join our group🧬Working with genomic and transcriptomic data obtained from patients diagnosed with lymphoid malignancies. Focus in single cell multi-omics data. #bioinformatics #researcher
https://t.co/1aec9kZPvc
0
1
4
@HemaClinicoVLC @gellc @MartaCrespoHEM @VHIO e @ixazebe @DonostiakoOsp analizan la utilización del sistema inmune en la #LLC @US_FDA ha aprobado por primera vez una terapia #CART para la #LLC tras fallar otros tratamientos. Los #ensayos muestran respuestas duraderas y abren una vía de #esperanza para
1
8
15
María José Terol @HemaClinicoVLC analiza los mecanismos de #resistencia y estrategias frente a #BTK @gellc
1
3
4
Seguimos en el 7 Curso Práctico para el #Conocimiento y #Tratamiento de la #Leucemia Linfocítica Crónica #LLC con Sergio Ramos Cillán @Hospital_FJD que da algunas #pautas para fomentar el #empoderamiento del paciente @gellc
1
7
13
Comienza el 7 Curso Práctico para el #Conocimiento y Tratamiento de la #Leucemia Linfocítica Crónica #LLC #gellc2026 en #Santander
1
7
15
Ampliamos equipo! Buscamos hematólogo/a para la Unidad de Ensayos Clínicos @Hemato_Vhebron y otros proyectos científicos🩺🧪 Te apuntas? (Contactar secretaria-hemato@vhio.net)
0
16
22
🚨Thrilled to share our latest work, published online today @Nature in which we decipher mechanisms underlying the enigmatic VEXAS syndrome - a huge team effort @MSKCancerCenter led by superstars @VarunNarendraMD + @das_tandrila 🧵1/ https://t.co/0ubLHCbR9I
nature.com
Nature - Independent mechanisms of inflammation and myeloid bias in VEXAS syndrome
10
38
142
#CLL Among the more interesting CLL abstracts at ASH: Pirto vs Ibrutinib in both TN and RR CLL. Non-inferiority of ORR, PFS not mature. Tox favors pirto. Does anyone want pirto to jump the covalent inhibitors? https://t.co/q28zMNSaTB
2
3
25
#CLL and the biggest of all: CLL17 out - very impressive study: I vs IV, vs Obi-Ven. Non-inferiority of fixed duration regimen vs continuous ibrutinib. https://t.co/KJXfbnf4Ql Feels like the field is ready for randomized MRD guided vs Fixed duration!
1
6
48
📢Oferta de #empleoSEHH ⬇️⬇️⬇️ 🏥🧪El laboratorio del Hospital @vallhebron busca un hematólogo para el área de diagnóstico citomorfológico y molecular de patologías hematológicas. ¡No pierdas esta oportunidad! 👉 https://t.co/mk7xKd47N6
#HematoEnRed #SEHHematología @sehh_es
0
5
5
#Hematology Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab #lymsm #RWE
ashpublications.org
Key PointsBispecifics had an ORR and CR rate of 51.7% and 25.4%, respectively; median PFS and OS were 2.5 and 7.8 months, respectively.Undetectable CD20 at
2
5
23
#Hematology Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for #CLL/SLL #lymsm
ashpublications.org
Key PointsIn the final analysis of RESONATE-2, survival and PFS benefits of ibrutinib treatment were sustained, with median PFS reached at 8.9 years.Ibruti
0
4
16
Shame on you @Aetna for putting up this absurd barrier to limit a desperate cancer patient’s access to amivantanab, while pretending to have more oncology expertise than do this physician patient’s own oncologists, our guideline committees, and the @FDA. @DGlaucomflecken
From Dr. Bryant Lin, Stanford I'm living in insurance hell!!! 1) I am a Stage 4 Lung Cancer patient and advocate. 2) As a medical school Clinical Professor, I taught a class at Stanford anchored around my own case which was covered widely in the The New York Times, CBS Mornings,
0
6
17
#Hemato2025 | 👨⚕️@ab_pau, de @Hemato_Vhebron, revisa las estrategias para mejorar la 1L de tratamiento en el simposio NUEVAS PERSPECTIVAS EN EL DIAGNÓSTICO Y TRATAMIENTO DE LOS #LCBG ⬇️⬇️⬇️ #HematoEnRed #SEHHematologia #linfoma #cancersanguineo
0
2
9
Honored to share our newly published manuscript https://t.co/HrqUuNK4CM which demonstrates that circulating tumor DNA (ctDNA) by PhasED-Seq offers the most precise definition of remission after frontline therapy for patients with large B-cell lymphoma (LBCL) out now in @JCO_ASCO.
ascopubs.org
Journal of Clinical Oncology (JCO) is a high-impact, peer-reviewed medical journal that publishes significant clinical oncology research along with editorials, reviews, and other works that relate to...
4
23
68
The immune system is powerful. Sometimes, too powerful. If it goes unchecked, it can turn on us - attacking our own organs, tissues, even our blood. That’s why the 2025 Nobel Prize in Medicine matters so much. It honors three scientists who figured out how the body stops
91
1K
4K
Reunión del Grupo Español de Leucemia Linfocítica Crónica en el congreso anual de @sehh_es 📆 viernes, 10 octubre 2025 ⌚️ 18:45-20:15h
#SAVETHEDATE Reunión del Grupo Español de Leucemia Linfocítica Crónica en el congreso anual de @sehh_es 📆 viernes, 10 octubre 2025 🕖 18:45-20:15h 📍 Palacio de Congresos de Oviedo, Sala 9+10 ¡Te esperamos!
0
1
6
BREAKING NEWS The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”
467
12K
29K
Primera sesión del último día en #iwCLL2025. Novel therapies: non-immunological approaches, moderada por el Dr. Bosch y la Dra. Woyach @sehh_es @SEHHJoven #CLL
0
4
13